<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03767881</url>
  </required_header>
  <id_info>
    <org_study_id>E7108</org_study_id>
    <nct_id>NCT03767881</nct_id>
  </id_info>
  <brief_title>AXIOS™ for Gallbladder Drainage as an Alternative to Percutaneous Drainage IDE</brief_title>
  <official_title>A Multicenter, Prospective Study of EUS-Guided Transluminal Gallbladder Drainage in Patients With Acute Cholecystitis as an Alternative to Percutaneous Gallbladder Drainage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and effectiveness of the AXIOS™ Stent with Electrocautery Enhanced
      Delivery System in the management of symptoms of acute cholecystitis as an alternative to
      percutaneous gallbladder drainage.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, single arm, multi center trial. Treatment of up to 30 patients
      will take place at up to 9 clinical centers. Patients who meet all eligibility criteria will
      receive the AXIOS stent for up to 60 days indwell and 72 hour follow-up after stent removal.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 10, 2019</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Resolution of Acute Cholecystitis</measure>
    <time_frame>Up to 15 weeks</time_frame>
    <description>Time to resolution of acute cholecystitis measured in days. Resolution is defined as either a fever of less than 100.5°F, or at least a 4-point decrease in the pain score, or WBC count less than 12,000/cc, with improvement in at least two of these categories without the deterioration of the third category.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of re-interventions</measure>
    <time_frame>Through study completion, Up to 15 weeks</time_frame>
    <description>Rate of re-interventions including but not limited to stent migration, stent occlusion by GB stones, and luminal debridement.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Stent Patency</measure>
    <time_frame>Intraoperative (Stent placement through stent removal)</time_frame>
    <description>Stent patency (ability to facilitate gallbladder drainage) defined indirectly as resolution of acute cholecystitis or, in the absence of resolution of acute cholecystitis, endoscopic observation of unobstructed AXIOSTM stent lumen</description>
  </other_outcome>
  <other_outcome>
    <measure>Technical stent placement success</measure>
    <time_frame>Intraoperative (stent placement)</time_frame>
    <description>Technical AXIOS stent placement success, defined as transmural placement of the AXIOSTM stent with confirmed stent patency via (i) drainage visualized through the stent or fluoroscopically, or (ii) ability to endoscopically observe the inner walls of the gallbladder through the AXIOSTM stent</description>
  </other_outcome>
  <other_outcome>
    <measure>Technical stent removal success</measure>
    <time_frame>Intraoperative (stent removal)</time_frame>
    <description>Technical stent removal success, defined as the ability to remove the AXIOS stent endoscopically without stent removal related serious adverse events</description>
  </other_outcome>
  <other_outcome>
    <measure>Acute Cholecystitis recurrence</measure>
    <time_frame>Through study completion, up to 15 weeks</time_frame>
    <description>Recurrence of acute cholecystitis and its management post AXIOS stent removal</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of cumulative hospital and ICU days</measure>
    <time_frame>Through study completion, up to 15 weeks</time_frame>
    <description>Number of cumulative hospital and ICU days from initial stent placement to resolution of symptoms of acute cholecystitis</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Cholecystitis, Acute</condition>
  <arm_group>
    <arm_group_label>AXIOS(TM) Stent and Electrocautery Enhanced Delivery System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who are at high risk or unsuitable for surgery will receive an AXIOS stent under EUS guidance for treatment of acute cholecystitis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AXIOS(TM) Stent and Electrocautery Enhanced Delivery System</intervention_name>
    <description>Patients who are at high risk or unsuitable for surgery will receive an AXIOS stent under EUS guidance for treatment of acute cholecystitis.</description>
    <arm_group_label>AXIOS(TM) Stent and Electrocautery Enhanced Delivery System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient requiring intervention for the management of symptoms associated with acute
             cholecystitis

          2. Patients referred for percutaneous drainage of the gallbladder who are not surgical
             candidates because of advanced age, anesthetic risk, significant co-morbidities and/or
             overall health

          3. Eligible for endoscopic intervention

          4. Acute Cholecystitis (AC) Grade I (mild) or II (moderate) per Tokyo guidelines:

               -  AC Grade I (mild) defined as acute cholecystitis in an otherwise healthy patient
                  with mild local inflammatory changes and without organ dysfunction. Criteria for
                  grade II or III not met.

               -  AC Grade II (moderate) defined by any one of the following characteristics

                    -  Leukocytosis (&gt;18,000 cells per mm3)

                    -  Palpable, tender mass in right upper quadrant

                    -  Symptom duration &gt;72 hours

                    -  Marked local inflammation (gangrenous or emphysematous cholecystitis,
                       pericholecystic or hepatic abscess, biliary peritonitis)

          5. Pre-drainage imaging confirms sufficient stone-free space to allow AXIOS™ stent
             deployment and complete flange expansion

          6. 18 years of age or older

          7. Willing and able to comply with the study procedures and patient or legally authorized
             representative (LAR) must provide written informed consent form (ICF) to participate
             in the study

        Exclusion Criteria:

          1. AC Grade III (severe) per Tokyo guidelines defined by organ dysfunction in any one of
             the following systems:

               -  Cardiovascular - Hypotension requiring administration of ≥5μg/kg/min of dopamine
                  or any dose of norepinephrine

               -  Neurologic - decreased level of consciousness

               -  Respiratory - PaO2/FiO2 &lt;300

               -  Renal - Oliguria and Creatinine &gt;2.0 mg/dl (&gt;177 μmol/liter)

               -  Hepatic - International normalized ratio &gt;1.5

               -  Hematologic - Platelet count &lt;100,000/mm3

          2. Obvious signs on diagnostic imaging of perforated, extensive gangrenous or ischemic
             gallbladder

          3. Hepatic abscess

          4. Ascites

          5. Patients with abnormal coagulation or who require ongoing complete anticoagulation

          6. Bleeding diathesis

          7. History of surgical treatment of acute cholecystitis (e.g. cholecystectomy)

          8. Patients with a current percutaneous drainage

          9. Patients with a history of percutaneous gallbladder drainage without AC free period
             following percutaneous drainage removal

         10. Distance between gallbladder wall and duodenal or gastric wall &gt; 1cm by US
             (ultrasound) at the time of drainage

         11. Patients with intervening gastric varices or vessels within a one centimeter radius of
             the device insertion location

         12. Patients that have allergies or are sensitive to any of the device materials

         13. Patients with contraindications to use of electrical devices

         14. Pregnancy

         15. Prisoners and other vulnerable populations
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shayan Irani, MBBS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Mason Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Evelyne Ho</last_name>
    <phone>(978) 483-8856</phone>
    <email>Evelyne.Ho@bsci.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lina Ginnetti</last_name>
    <phone>(617) 216-6699</phone>
    <email>Lina.Ginnetti@bsci.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raj J Shah, MD, FASGE, AGAF</last_name>
      <phone>(720) 848-2786</phone>
      <email>Raj.Shah@ucdenver.edu</email>
    </contact>
    <investigator>
      <last_name>Raj Shah</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Field F Willingham</last_name>
      <email>Field.Willingham@emory.edu</email>
    </contact>
    <contact_backup>
      <phone>(404) 778-3184</phone>
    </contact_backup>
    <investigator>
      <last_name>Field F Willingham, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Parkview Medical Center</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46845</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neil Sharma, MD</last_name>
      <phone>260-266-1017</phone>
      <email>Neil.Sharma@parkview.com</email>
    </contact>
    <investigator>
      <last_name>Neil Sharma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrew Storm, MD</last_name>
      <phone>507-284-2174</phone>
      <email>Storm.Andrew@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Andrew Storm, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shavan Irani, MBBS, MD</last_name>
      <phone>206-223-2319</phone>
      <email>Shayan.Irani@virginiamason.org</email>
    </contact>
    <investigator>
      <last_name>Shayan Irani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>B-3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Schalk W van der Merwe, MD, MSc, PhD</last_name>
      <phone>32 16 34 42 99</phone>
      <email>Schalk.Vandermerwe@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Schalk W van der Merwe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Université de Montréal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2W 1T8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anand Sahai, MD, MSc, FRCPC</last_name>
      <phone>(514) 890 - 8000</phone>
      <phone_ext>34373</phone_ext>
      <email>Anandvsahai@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Anand Sahai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>December 4, 2018</study_first_submitted>
  <study_first_submitted_qc>December 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2018</study_first_posted>
  <last_update_submitted>June 25, 2020</last_update_submitted>
  <last_update_submitted_qc>June 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AXIOS</keyword>
  <keyword>Acute Cholecystitis</keyword>
  <keyword>Percutaneous Gallbladder Drainage</keyword>
  <keyword>Cholecystitis</keyword>
  <keyword>Gallbladder Drainage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholecystitis</mesh_term>
    <mesh_term>Acalculous Cholecystitis</mesh_term>
    <mesh_term>Cholecystitis, Acute</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

